Suppression of BRAFV599E in human melanoma abrogates transformation

Sunil R. Hingorani, Michael A. Jacobetz, Gavin P. Robertson, Meenhard Herlyn, David A. Tuveson

Research output: Contribution to journalArticle

366 Scopus citations

Abstract

Activating mutations in the BRAF serine/threonine kinase are found in >70% of human melanomas, of which >90% are BRAFV599E. We sought to investigate the role of the BRAFV599E allele in malignant melanoma. We here report that suppression of BRAFV599E expression by RNA interference in cultured human melanoma cells inhibits the mitogen-activated protein kinase cascade, causes growth arrest, and promotes apoptosis. Furthermore, knockdown of BRAFV599E expression completely abrogates the transformed phenotype as assessed by colony formation in soft agar. Similar targeting of BRAFV599E or wild-type BRAF in human fibrosarcoma cells that lack the BRAFV599E mutation does not recapitulate these effects. Moreover, these results are specific for BRAF, as targeted interference of CRAF in melanoma cells does not significantly alter their biological properties. Thus, when present, BRAFV599E appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation.

Original languageEnglish (US)
Pages (from-to)5198-5202
Number of pages5
JournalCancer Research
Volume63
Issue number17
Publication statusPublished - Sep 1 2003

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003). Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Research, 63(17), 5198-5202.